Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed By Investing.com
    News

    Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed By Investing.com

    userBy userDecember 29, 2024No Comments3 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email



    Radnor, Pennsylvania–(Newsfile Corp. – December 29, 2024) – The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (“IPO”). The lead plaintiff deadline is February 7, 2025.

    CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:

    If you suffered Kyverna losses, you may CLICK HERE or copy and paste this link into your browser: https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=kytx&mktm=r

    You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com.

    DEFENDANTS’ ALLEGED MISCONDUCT:

    The complaint alleges that, in the prospectus and registration statements issued in connection with the IPO, Defendants made materially false and/or misleading statements and/or omissions regarding the company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements regarding, and/or failed to disclose, that Kyverna possessed adverse data related to one of its clinical trials at the time of its IPO.

    THE LEAD PLAINTIFF PROCESS:

    Kyverna investors may, no later than February 7, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

    Kessler Topaz Meltzer & Check, LLP encourages Kyverna investors who have suffered significant losses to contact the firm directly to acquire more information.

    CLICK HERE TO SIGN UP FOR THE CASE OR COPY AND PASTE THIS LINK INTO YOUR BROWSER: https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=kytx&mktm=r

    ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

    CONTACT:

    May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235392





    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleAzerbaijan’s president says crashed plane was shot at from Russia By Reuters
    Next Article Roche has no plans for job cuts and business is healthy, CEO says
    user
    • Website

    Related Posts

    EdFed Awards Personal Finance Certifications to South Florida High School Students

    May 20, 2025

    Apollo Global Management Eyes $1 Billion in Private Credit for PowerGrid Buyout

    May 20, 2025

    3 FTSE 100 shares that could help propel the index higher

    May 20, 2025
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d